SEC Form 4 · accession 0000891293-15-000017
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jack W Singer
Officer — EVP, Global Medical Affairs · Director
Period of report
Apr 24, 2015
Accepted (ET)
Apr 27, 2015 · 5:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 24, 2015 | S | 600 | $1.94 | D | 1,335,319 | D | |
| Common Stock | Apr 24, 2015 | S | 1,100 | $1.945 | D | 1,334,219 | D | |
| Common Stock | Apr 24, 2015 | S | 1,900 | $1.95 | D | 1,332,319 | D | |
| Common Stock | Apr 24, 2015 | S | 1,200 | $1.955 | D | 1,331,119 | D | |
| Common Stock | Apr 24, 2015 | S | 3,440 | $1.96 | D | 1,327,679 | D | |
| Common Stock | Apr 24, 2015 | S | 300 | $1.962 | D | 1,327,379 | D | |
| Common Stock | Apr 24, 2015 | S | 60 | $1.965 | D | 1,327,319 | D | |
| Common Stock | Apr 24, 2015 | S | 3,200 | $1.97 | D | 1,324,119 | D | |
| Common Stock | Apr 24, 2015 | S | 3,200 | $1.98 | D | 1,320,919 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale was effected pursuant to a Rule 10b5-1 trading plan.